First‐in‐Human Phase I Study of MBC‐11 a Novel Bone‐Targeted Cytarabine‐Etidronate Conjugate in Patients with Cancer‐Induced Bone Disease

摘要

Lessons Learned. class="unordered" style="list-style-type:disc" id="onco12741-list-0001">

Results are consistent with MBC‐11 targeting and treating cancer‐induced bone lesions by concentrating cytarabine and etidronate at the site of disease.

MBC‐11 was well tolerated, with an maximum tolerated dose of 5 mg/kg per day and myelosuppression as the principal toxicity.

Treatment significantly reduced cancer cell activity in over half of bone lesions detected at baseline.

MBC‐11 pharmacokinetic and pharmacodynamic parameters are consistent with the novel drug design goals, and encouraging results warrant further clinical development.